{
    "clinical_study": {
        "@rank": "34951", 
        "acronym": "GECP0008", 
        "arm_group": [
            {
                "arm_group_label": "Docetaxel +Carboplatin +concomitant chemoradiation", 
                "arm_group_type": "Experimental", 
                "description": "Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered)  and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)"
            }, 
            {
                "arm_group_label": "C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom", 
                "arm_group_type": "Experimental", 
                "description": "Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)"
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized study in 2 arms, without any masking in patients with non small cell lung cancer,\n      histologically or cytologically confirmed, not liable to surgery, stage IIIB or IIIA,\n      according to the TNM classification of the American Joint Committee for cancer. In one arm\n      will be administered concomitant radiotherapy and carboplatin-docetaxel-gemcitabine followed\n      by docetaxel and, in the other  arm will be administered docetaxel-gemcitabine followed by\n      concurrent radiotherapy with carboplatin-docetaxel"
        }, 
        "brief_title": "Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "December 2007", 
            "@type": "Actual"
        }, 
        "condition": "Non Small-cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Unresectable stage IIIA or B NSCLC patients\n\n          -  WHO PS 0 or 1\n\n          -  Weight loss < 5 %  within the last 3 months\n\n          -  At least one measurable lesion\n\n          -  Planning CT scan previous to randomization\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Malignant effusion, supraclavicular node or SVCS\n\n          -  PTV > 2000 cm3\n\n          -  V20 > 35%\n\n          -  FEV1  and DLCO both < 30% or 1 liter at study entry"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652820", 
            "org_study_id": "GECP 00-08 / TAX.ES1.209"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Docetaxel +Carboplatin +concomitant chemoradiation", 
                    "C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom"
                ], 
                "intervention_name": "Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation  2Gy/day", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Docetaxel +Carboplatin +concomitant chemoradiation", 
                    "C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom"
                ], 
                "intervention_name": "Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT  2Gy/d", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Docetaxel", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "LUNG", 
            "DOCETAXEL", 
            "GEMCITABINE", 
            "CARBOPLATIN", 
            "RADIOTHERAPY"
        ], 
        "lastchanged_date": "July 27, 2012", 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Trial Using Concomitant Chemoradiation Plus Induction or Consolidation Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer Patients", 
        "overall_official": [
            {
                "affiliation": "Hospital Ramon y Cajal (Madrid)", 
                "last_name": "Pilar Garrido, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL", 
                "last_name": "Rafael Rosell, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652820"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Local control rate at 1 year", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No"
            }
        ], 
        "source": "Spanish Lung Cancer Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Aventis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Spanish Lung Cancer Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}